Franklin Genomic Advancements Etf Probability of Future Etf Price Finishing Under 29.44
| HELX Etf | USD 29.53 0.29 0.99% |
Franklin |
Franklin Genomic Target Price Odds to finish below 29.44
The tendency of Franklin Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 29.44 or more in 90 days |
| 29.53 | 90 days | 29.44 | roughly 2.19 |
Based on a normal probability distribution, the odds of Franklin Genomic to drop to $ 29.44 or more in 90 days from now is roughly 2.19 (This Franklin Genomic Advancements probability density function shows the probability of Franklin Etf to fall within a particular range of prices over 90 days) . Probability of Franklin Genomic Adv price to stay between $ 29.44 and its current price of $29.53 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Franklin Genomic has a beta of 0.99. This usually indicates Franklin Genomic Advancements market returns are sensitive to returns on the market. As the market goes up or down, Franklin Genomic is expected to follow. Additionally Franklin Genomic Advancements has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Franklin Genomic Price Density |
| Price |
Predictive Modules for Franklin Genomic
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Franklin Genomic Adv. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Franklin Genomic Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Franklin Genomic is not an exception. The market had few large corrections towards the Franklin Genomic's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Franklin Genomic Advancements, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Franklin Genomic within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.29 | |
β | Beta against Dow Jones | 0.99 | |
σ | Overall volatility | 1.20 | |
Ir | Information ratio | -0.24 |
Franklin Genomic Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Franklin Genomic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Franklin Genomic Adv can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Franklin Genomic Adv generated a negative expected return over the last 90 days | |
| Latest headline from news.google.com: Investment Analysis and Advice - Stock Traders Daily | |
| The fund created three year return of -17.0% | |
| Franklin Genomic Adv retains 98.96% of its assets under management (AUM) in equities |
Franklin Genomic Technical Analysis
Franklin Genomic's future price can be derived by breaking down and analyzing its technical indicators over time. Franklin Etf technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Franklin Genomic Advancements. In general, you should focus on analyzing Franklin Etf price patterns and their correlations with different microeconomic environments and drivers.
Franklin Genomic Predictive Forecast Models
Franklin Genomic's time-series forecasting models is one of many Franklin Genomic's etf analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Franklin Genomic's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the etf market movement and maximize returns from investment trading.
Things to note about Franklin Genomic Adv
Checking the ongoing alerts about Franklin Genomic for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Franklin Genomic Adv help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Franklin Genomic Adv generated a negative expected return over the last 90 days | |
| Latest headline from news.google.com: Investment Analysis and Advice - Stock Traders Daily | |
| The fund created three year return of -17.0% | |
| Franklin Genomic Adv retains 98.96% of its assets under management (AUM) in equities |
Check out Franklin Genomic Backtesting, Portfolio Optimization, Franklin Genomic Correlation, Franklin Genomic Hype Analysis, Franklin Genomic Volatility, Franklin Genomic History as well as Franklin Genomic Performance. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.